Granite Point Capital Management’s Regenxbio RGNX Stock Holding History

Granite Point Capital Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-60,000	Closed	-$1.59M	–	107
2022 Q3	$1.59M	Hold	60,000	–	–	0.64%	27
2022 Q2	$1.48M	Buy	+60,000	New	+$1.5M	0.38%	33
2019 Q1	–	Sell	-47,500	Closed	-$1.99M	–	127
2018 Q4	$1.99M	Hold	47,500	–	–	0.4%	38
2018 Q3	$3.59M	Sell	47,500 -2,600	-5%	-$187K	0.24%	39
2018 Q2	$3.6M	Sell	50,100 -24,900	-33%	-$1.19M	0.32%	33
2018 Q1	$2.24M	Buy	+75,000	New	+$2.18M	0.22%	31

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Granite Point Capital Management's RGNX Position: Q4 2022 in Review

Granite Point Capital Management sold out of Regenxbio (RGNX) in Q4 2022, closing a stake of 60,000 shares — an estimated $1.59M sold.

Granite Point Capital Management first reported a position in RGNX in Q1 2018 and held it in 6 quarters. The position peaked at $3.6M in Q2 2018. 182 funds tracked by Wall St. Rank hold RGNX as of Q4 2022.

Granite Point Capital Management reported no remaining Regenxbio position as of Q4 2022 after selling out during the quarter.
Granite Point Capital Management sold 60,000 Regenxbio shares in Q4 2022, an estimated $1.59M.
Granite Point Capital Management first reported a position in Regenxbio in Q1 2018 and held it in 6 quarters.
Granite Point Capital Management's Regenxbio position peaked at $3.6M in Q2 2018.
182 funds tracked by Wall St. Rank held Regenxbio as of Q4 2022.

Based on Granite Point Capital Management's 13F filing for Q4 2022, filed 7 Feb 2023.